|
Adenocarcinoma of lung (disorder)
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Adenocarcinoma of lung (disorder)
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Gastric Adenocarcinoma
|
0.320 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Adenocarcinoma of large intestine
|
0.310 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Large cell carcinoma of lung
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Short stature
|
0.100 |
CausalMutation
|
phenotype |
CLINVAR |
|
|
|
|
Abnormality of brain morphology
|
0.100 |
GeneticVariation
|
phenotype |
CLINVAR |
|
|
|
|
Fibrosis, Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> p66Shc is a redox enzyme that mediates mitochondrial reactive oxygen species (ROS) generation. p66Shc inhibition confers protection against liver injury, however, its functional contribution to liver fibrosis remains unclear.
|
30867846 |
2019 |
|
Anthrax disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>Ex vivo</i>, we found that freshly isolated human neutrophils can rapidly kill anthrax, with specific inhibitor studies showing that phagocytosis and reactive oxygen species (ROS) generation contribute to this efficient bacterial clearance.
|
29404280 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
<i>ROS1</i> rearrangements define a distinct molecular subset of non-small-cell lung cancer (NSCLC), which can be treated effectively with crizotinib, a tyrosine kinase inhibitor (TKI) targeting <i>ROS1/MET/ALK</i> rearrangements.
|
30940295 |
2019 |
|
Retinoblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
(3) Results: Treatment with Rb1 significantly increased the cell viability and mtDNA copy number, and inhibited ROS generation.
|
31590397 |
2019 |
|
Amyloidosis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
(intraperitoneal) administration of VA (30 mg/kg, for 3 weeks) after Aβ<sub>1-42</sub>-injection enhanced glutathione levels (GSH) and abrogated ROS generation accompanied by an induction of the endogenous nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) via the activation of Akt and glycogen synthase kinase 3β (GSK-3β) in the brain mice.
|
28098243 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
- Although fluorescence in situ hybridization remains the gold standard for detecting ALK and ROS1 rearrangement in non-small cell lung cancer, immunohistochemistry plays an important role and can be an effective screening method for detection of these genetic alterations, or a diagnostic test in the setting of ALK.
|
29902067 |
2018 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
- To review the role of immunohistochemistry in assessment of ALK and ROS1 rearrangements in lung cancer, focusing on practical issues in comparison with other modalities such as fluorescence in situ hybridization.
|
29902067 |
2018 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
- To review the role of immunohistochemistry in assessment of ALK and ROS1 rearrangements in lung cancer, focusing on practical issues in comparison with other modalities such as fluorescence in situ hybridization.
|
29902067 |
2018 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
- To review the role of immunohistochemistry in assessment of ALK and ROS1 rearrangements in lung cancer, focusing on practical issues in comparison with other modalities such as fluorescence in situ hybridization.
|
29902067 |
2018 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
19 tumors were identified with ROS1 rearrangement (3.7% of adenocarcinomas).
|
27708233 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
3'-Hydroxy-4'-methoxy-β-methyl-β-nitrostyrene inhibits tumor growth through ROS generation and GSH depletion in lung cancer cells.
|
28007499 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
5' ROS1 deletions detected by FISH are associated with a high chance of response to Crizotinib in NSCLC, similarly to canonical ROS1 split-apart FISH rearrangements.
|
31447007 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.160 |
Biomarker
|
disease |
BEFREE |
7-KC increased ROS generation by LMSCs, which was related to decreased cell viability.
|
31117185 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
73 patients with lung adenocarcinomas were identified: 17 (23%) with ROS1 fusions, 25 (34%) with RET fusions and 31 (43%) with EGFR mutations.
|
26424208 |
2015 |
|
Mitochondrial Respiratory Chain Deficiencies
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Respiratory chain deficiency slows down cell-cycle progression via reduced ROS generation and is associated with a reduction of p21CIP1/WAF1.
|
16775840 |
2006 |
|
Carcinoma, Ovarian Epithelial
|
0.040 |
Biomarker
|
disease |
BEFREE |
Ovarian cancer is primarily treated with platinum-based chemotherapy, with ROS generation implicated in cytotoxicity.
|
20650313 |
2010 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ovarian cancer is primarily treated with platinum-based chemotherapy, with ROS generation implicated in cytotoxicity.
|
20650313 |
2010 |
|
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ovarian cancer is primarily treated with platinum-based chemotherapy, with ROS generation implicated in cytotoxicity.
|
20650313 |
2010 |